Skip to main content

Table 3 Difference in ΔeGFR and the risk of adverse renal events according to quartile of urinary A-megalin

From: Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study

 Quartile of urinary A-megalinP
Q1 (n = 11)Q2 (n = 12)Q3 (n = 11)Q4 (n = 11)
ΔeGFR (mL/min/1.73 m2)−3.8±6.7−15.2±15.1−11.9±18.0−20.8±18.50.085a
Estimated difference (95% CI) from Q1 (mL/min/1.73 m2)
 Crude0.00(reference)−11.39(−24.30, 1.51)+−8.05(−21.23, 5.14)−16.95(−30.13, −3.76)*0.018b
 Adjusted0.00(reference)−10.00(−22.29, 2.38)−4.94(−17.73, 7.85)−13.27(−26.17, −0.37)*0.064b
Adverse renal events / person-days2/ 1947/ 1466/ 1299/ 95 
Event rate (/10 person days)0.1030.4790.4650.947 
Hazard ratio (95% CI)
 Crude1.00(reference)4.25(0.88, 20.51)+4.04(0.81, 20.09)+7.24(1.55, 33.96)*0.008b
 Adjusted1.00(reference)3.80(0.78, 18.48)+3.03(0.60, 15.30)4.39(0.91, 21.13)+0.093b
  1. CI, confidence interval; eGFR, estimated glomerular filtration rate. ΔeGFR, maximum change from the baseline value to the lowest value of eGFR during follow-up. An adverse renal event was defined as an eGFR decline of > 10 mL/min/1.73 m2. Adjusted hazard ratio, adjusted for baseline eGFR. +P < 0.1, *P < 0.05, aP for statistical difference between groups, bP for trend